rNAPc2 (AB201)
being developed as a potential treatment for severe COVID-19
Phase 2b

clinical trial began enrolling patients Dec 2020; topline data anticipated 2Q2021
A Late Stage Biopharma Company
Tailored Healthcare
Pharmacogenetic Precision Medicine for Cardiovascular Disease
30-60%

Individual patients respond differently to their disease and treatment.
Only 1/3 to 2/3 of common drug therapy is successful.
Atrial Fibrillation
An Epidemic Cardiovascular Disease
5.2 M

Estimated number of individuals diagnosed with AF in U.S. in 2015.
Unmet Medical Need
Safe and effective drug therapies for atrial fibrilation in patients with heart failure
Zero

There are currently no FDA approved drug therapies indicated for treating patients
with atrial fibrillation and heart failure with left ventricular ejection fraction (LVEF) >= 40%.
Gencaro™
Potentially the first genetically-targeted AF treatment
50%

Approximate % of U.S. population with genotype that responds most favorably to Gencaro™.
PRECISION-AF Clinical Trial
Evaluating Gencaro™ as a genetically-targeted therapy for atrial fibrillation in patients with heart failure
Phase 3

Initiation of PRECISION-AF anticipated 2021

rNAPc2 (AB201)
being developed as a potential treatment for severe COVID-19
Phase 2b

clinical trial began enrolling patients Dec 2020; topline data anticipated 2Q2021
A Late Stage Biopharma Company
Tailored Healthcare
Pharmacogenetic Precision Medicine for Cardiovascular Disease
30-60%

Individual patients respond differently to their disease and treatment.
Only 1/3 to 2/3 of common drug therapy is successful.
Atrial Fibrillation
An Epidemic Cardiovascular Disease
5.2 M

Estimated number of individuals diagnosed with AF in U.S. in 2015.
Unmet Medical Need
Safe and effective drug therapies for atrial fibrilation in patients with heart failure
Zero

There are currently no FDA approved drug therapies indicated for treating patients
with atrial fibrillation and heart failure with left ventricular ejection fraction (LVEF) >= 40%.
Gencaro™
Potentially the first genetically-targeted AF treatment
50%

Approximate % of U.S. population with genotype that responds most favorably to Gencaro™.
PRECISION-AF Clinical Trial
Evaluating Gencaro™ as a genetically-targeted therapy for atrial fibrillation in patients with heart failure
Phase 3

Initiation of PRECISION-AF anticipated 2021
hex-our-focus

Our Focus

Precision Medicine

Precision medicine refers to the tailoring of medical treatment to the individual characteristics of each patient…

[+more]

Coronavirus and COVID-19

COVID-19 is the disease caused by SARS-CoV-2, a new coronavirus identified in late 2019.  As of November 2020, there is no approved curative therapy for COVID-19.

Cardiovascular Disease and Atrial Fibrillation

Cardiovascular disease is the No. 1 cause of death in the United States and a major economic burden on the healthcare system…

[+more]

rNAPc2- A Potential Treatment for COVID-19

rNAPc2 (AB201) is a potent, selective inhibitor of tissue factor (TF), which has been identified as playing a central role in the inflammatory response to viral infections and in the process of viral dissemination. Its unique mechanism of action gives rNAPc2 a combination of anti-coagulant, immuno-modulation and anti-viral properties, and therefore the potential to be effective in addressing the pathologies caused by viral infections from multiple aspects.

Gencaro™ — An Unmet Need

pill

Gencaro™ is a pharmacologically unique beta-blocker and mild vasodilator that we are evaluating in a clinical trial for the treatment of atrial fibrillation…

[+more]
hex-gencaro

Gencaro™